Skip to main content
ConductScienceScienceDex

Paul Douglas Godfrin

NIH Rank #36538
Unclaimed recordClaim profile
  • Early Career

Researcher identity and coverage

Current affiliation
Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
NIH RePORTER identity
Profile ID 15260416Search this ID in NIH RePORTER
ScienceDex PI coverage
FY2025 onlyCareer claims are limited to the years shown.Metrics use this researcher's latest loaded PI award year; ScienceDex is current through FY2026.

NIH Funding · FY2025

Linked Award Amount
$400K
Full award amounts, FY2025
Award Records
1
Records listing this PI
Award-Linked Rank
#36,538
By linked amount among FY2025 PIs
Earliest Year Loaded
2025
ScienceDex PI coverage

One scientist record

NIH portfolios and SHARE

This is the common ScienceDex page for Paul Douglas Godfrin. NIH portfolio memberships are contextual views of this scientist, while SHARE Score, S-Index, and S-Impact describe the researcher's global sharing track record.

Review metric definitions

FY2025 NIH portfolio memberships

No institute-level portfolio release is available for this scientist and fiscal year yet. Existing award history remains unchanged above.

Researcher-associated datasets

These datasets are linked to this researcher's ShareScore identity. This does not by itself prove that an NIH portfolio funded each dataset.

No compatible author-to-dataset release is published. Dataset records are unavailable, not zero.

Award data coverage

ScienceDex currently has one fiscal year of PI ranking data for this record. This does not establish the first NIH award or current employer.

Single fiscal year on record (FY2025): $400K in linked award amounts across 1 award record · Award-linked rank #36538.

FY2025 award records by amount

NIH award records listing Paul Douglas Godfrin as a PI. Multi-PI records show the full award amount for context.

  • 1R44CA306533-01R44
    Preclinical validation of an effective oral fulvestrant product as the future standard of care endocrine therapy for ER+ metastatic breast cancer
    Veramorph, Llc
    $400K
    award amount

Award organization

Organizations that administered FY2025 awards listing Paul Douglas Godfrin as a PI.

FY2025 award administered by Veramorph, Llc (MA).

Coverage and award-record milestones

Computed from the fiscal years currently available in ScienceDex.

  1. 2025
    First NIH Award
    Veramorph, Llc

Explore further

Find collaborators for Paul Douglas Godfrin

Search NIH-funded principal investigators by topic, department, or activity.

Open Find Collaborators →

Benchmark grant budgets

Compare median NIH grant budgets across departments, mechanisms, and years.

Open Grant Budget Benchmark →